From its establishment in 2005, J-Pharma, a clinical stage bio-venture company with a special focus on membrane transporters, has been conducting an array of unique drug developments by Hitoshi Endou, MD., Ph.D., formerly a professor of Kyorin University Faculty of Medicine. Recently J-Pharma has been placing the highest priority on the clinical development of its original inhibitors of L-type amino acid transporter 1 (“LAT1”) for the treatment of advanced cancer patients who failed to benefit from standard chemotherapy.
Sonire has developed Next Gen US-guided HIFU therapy system using technology and know-how generated by Tokyo Women’s Medical University, Tohoku University and Tokyo Medical University for cancer treatment. It is expected to be a new therapeutic modality for intractable cancer like pancreatic cancer.
We produce and provide homogeneous and high precision human blood cells to drastically streamline the evaluation of efficacy and safety of drug candidates and functional materials, as well as the research of infectious diseases. We also sell evaluation kits and offer various contract evaluation services.
CarbGeM aims to overcome the problem of antimicrobial resistance through cutting-edge biology and digital technology, cross-industrial and cross-disciplinary collaboration including medicine and engineering, and industry-government-academia collaboration with world leading hospitals and research institutions. Our AI-based product assists physicians and laboratory technicians in estimating the species of bacterial infections and selecting appropriate antimicrobial agents.
iCorNet.Laboratory Co. is an academia driven medical device venture from Nagoya University Japan, developing the cardiac support net for heart failure and Lethal arrhythmia. Our device for HF is Patient-Specific Design and Manufactured by 3D knitting machine individually. It fills the treatment gap between ongoing drug therapy and heart transplantation (HTx), and is an alternative to Ventricular Assist Device (VAD)．Our device for lethal arrhythmia (ICD cardiac net) proves painless defibrillation (<0.7J) in both large animal model and computer simulation. Both devices have possibility to be gamechangers of current treatments.
aceRNA Technologies is a biotech startup established in 2018 based on RNA design technology developed in synthetic RNA biology research by Prof. Hirohide Saito at Kyoto University. We are developing "smart gene therapy” (mRNA-based and virus-base) that enables control of therapeutic transgene expression in cell-type and -state specific manner.
Celaid Therapeutics is an early stage Japan-based startup company that is based on the novel ex vivo expansion technology of hematopoietic stem cell invented at University of Tokyo and University of Tsukuba. Our mission is to develop cell therapy products that will be the next-generation stem cell transplantation.
A startup company from Keio University School of Medicine and Nagoya Institute of Technology, developing a visual restoration gene therapy using AAV (adeno-associated virus) vectors with the unique function gene “Chimeric Rhodopsin” to treat blindness.
atDose was founded on September 1, 2017 in Yokohama City, Kanagawa, Japan. We are developing a mobile-type dosing and infusion device that can dispense ultra-small doses at precise target points. The lightweight portable intravenous device can be used to support the treatment of diseases such as brain tumors, retinal disease, and breast cancer. With this device, we aim to create a medication platform that will fundamentally change the conventional treatment of serious diseases. For example, side effects such as stomatitis, hair loss, and nausea with anticancer drugs are one of eternal difficulty of medicine. Our ultra-micro-dosing device enables localized, targeted and continuous dosing. Thus, side effects should be reduced while maintaining the efficacy of the drug. Since an animal study has proved our device efficacy, we can go through clinical trial of any cancer therapy. Furthermore, any drug combination can be freely applied with newly approvable dosing amount, therefore, our device will be a novel drug delivery system as a platform technology. We also aim to improve patients' Quality of Life (QoL) with increasing the option of medication procedure. In addition to the conventional treatment, our platform technology will provide an additional procedure that respects patients' preference of QoL . We strongly believe this will improve present medication.
We have been working to bring unique acoustic inventions to markets for 16 years. Located in Tokyo, Japan. First product was a medical device called "Lung Flute" and it is currently used to find active Tuberculosis cases in developing countries. Now, we have developed and patented a new tire technology to contribute for future mobility society.
We are a startup to develop a novel tiny particle for unmet medical needs such as cancer and chronic pain, which particle is self-targeting to the tumor vessel, repeatable and degradable as a platform technology for further applications. Our unique particle is patent granted in Japan, now under transferring to the US, EU and China now. The first indication for human clinical trial will be HCC (hepato-cellular carcinoma) to replace TACE (trans-catheter chemoembolization) treatment which is the current primary option for the intermediate stage of HCC and to be a primary option other than shifting to chemotherapy. The other advantages are universal to every solid tumor, locoregional work at tumor tissue only, combinatory because of drug free and gentle for the weaken patient without additional physical burden. We can expect the extension of PFS (progression free survival) and OS (overall survival) rather than the high response of the advanced chemotherapy such as molecular target medicine and immunotherapy with severe side effects and drug escalations. The potential market for liver cancer only will be near 1 billion dollars per year. So, after the extension to the other solid tumors, it will be easily over several billions. The current definition of our particle is a medical device (category III by FDA), but it can become a functional matter after labeling other functions as a medicine. We are looking for the investors, collaboration partners and medical institutions for the global clinical trials.
OriCiro is focused on the development and commercialization of cell-free synthesis and amplification technology of genome-scale large DNA for applications in gene/cell-based therapy and synthetic biology. OriCiro's proprietary technology is positioned to unlock the possibility of advanced therapy and synthetic biology by providing a powerful tool used for research, development and manufacturing in multiple industries including pharmaceutical, diagnostics, agriculture and food sectors. The company is located in Tokyo, Japan.
Hynts Tech is a university startup established in July 2021. We develop and manufacture tools for introducing substances such as DNA, RNA, proteins, or intracellular organelles into cells, or for extracting intracellular materials, and to process cells using these tools.